Your Yourlocation: Home > Tiotropium bromide(136310-93-5) is the best in the treatment of refractory asthma

Asthma is a type of disease characterized by chronic airway inflammation, the current global incidence is getting higher and higher. Although there is a guideline for the treatment and control of asthma, a considerable number of patients still fail to gain effective control. Although there are already many targeted drugs are being developed, but the regular review and understanding of the progress of such tests is necessary.

Professor McIvor of McMaster University in Canada conducted a systematic retrospective study. The study found that tiotropium bromide(136310-93-5) is currently the best treatment of refractory asthma drugs. The article was recently published in the recent Ann Allergy Asthma Immunol magazine.

The study reviewed the clinical trials of and PubMed, respectively, reviewing advances in asthma studies over the past 10 years, including current trials of Phase 2 and Phase 3 clinical trials such as anti-interleukin monoclonal antibody (benralizumab, reslizumab, dupilumab, brodalumab, lebrikizumab, mepolizumab), type 2 T helper cell surface chemotactic receptor blockers, phosphodiesterase-4 inhibitors (lavine roflumilast), long acting muscarinic (M receptor) antagonists Long bromide, Tiotropium bromide(136310-93-5) and umeclidinium bromide).

The results showed that long-acting M receptor antagonist tiotropium bromide(136310-93-5) is currently involved in 2 and 3 clinical trials of the most asthma drugs, is currently one of the best feedback drug.

Current studies have shown that inhaled hormones combined with tiotropium in the treatment of severe refractory asthma. Current ongoing research and future studies require further attention and demonstrate the current control effect of new therapeutic agents on asthma.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved